GlassScriptPhysician profile
Kimberly Navratil
NPI 1417364936
$2,028.56
in general payments reported to CMS, 2019-2025
19 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Adult Health (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $293 · 2023: $382 · 2024: $712 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $493.29 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $478.94 | 2021-2025 | |
| Corium, LLC | $123.00 | 2023 | Azstarys |
| Silk Road Medical, INC. | $122.93 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Glaxosmithkline, LLC. | $122.15 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $121.17 | 2023 | Repatha |
| Dexcom, INC. | $105.02 | 2022-2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $96.94 | 2024 | Epclusa |
| Lilly USA, LLC | $92.15 | 2022-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $73.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Neurelis, INC. | $58.48 | 2024 | Valtoco |
| Medtronic, INC. | $28.53 | 2025 | Venaseal |
| Optinose US, INC. | $21.23 | 2025 | |
| Pfizer INC. | $18.72 | 2022 | |
| Astellas Pharma US INC | $17.08 | 2024 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $16.75 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Navratil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.